Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Presentation of Phase 3 Results for a PD-1 Immune Checkpoint Inhibitor
Boehringer Ingelheim's afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer
GENENTECH'S PERJETA REGIMEN EXTENDED THE LIVES OF PEOPLE WITH AN AGGRESSIVE TYPE OF METASTATIC BREAST CANCER BY 15.7 MONTHS COMPARED TO HERCEPTIN AND CHEMOTHERAPY
ZYTIGA(R) Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer
BASEL, Switzerland, Sept.
Health Care Equipment Equities under the Scanner - Medtronic, Abbott Laboratories, Stryker, Zeltiq Aesthetics, and EnteroMedics
Editor Note: For more information about this release, please scroll to bottom.
LONDON, September 26, 2014
Abbott Completes Acquisition of CFR Pharmaceuticals; Announces Results of Tender Offer for CFR Shares
Acquisition enhances Abbott's position in Latin America, more than doubling its branded generics pharmaceutical sales and presence in the fast-growing region